PALO ALTO, Calif., Aug. 14, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today financial results for the three months and six months ended June 30, 2017 and provided a business update.
"We continue to advance our pipeline of novel treatments for orphan indications with Phase 2 data expected across multiple clinical programs over the next 12 months," said David Cory, President and CEO of Eiger.
"We continue to advance our pipeline of novel treatments for orphan indications with Phase 2 data expected across multiple clinical programs over the next 12 months," said David Cory, President and CEO of Eiger.
